Bianca Weinstock-Gutman

IM interferon β-1a delays definite multiple sclerosis 5 years after a first demyelinating event

D. Arnold, J. Selhorst, R. Kinkel, 2006, Neurology.

Design, rationale, and baseline characteristics of the randomized double-blind phase II clinical trial of ibudilast in progressive multiple sclerosis.

J. Long, R. Conwit, S. Shinnar, 2016, Contemporary clinical trials.

IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event.

J. Selhorst, C. Kollman, R. Kinkel, 2006, Neurology.